Patents
Literature
97 results about "Pharmaceutical Excipient" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Pharmaceutical composition of heteroaryl derivative and application of pharmaceutical composition in medicine
A pharmaceutical composition or a pharmaceutical preparation, the pharmaceutical composition or the pharmaceutical preparation comprising a therapeutically effective amount of an active ingredient M and a pharmaceutical excipient, the active ingredient M being selected from a compound of general formula (I) or a stereoisomer, a tautomer, a deuterated compound, a solvate, a prodrug, a metabolite, a pharmaceutically acceptable salt or eutectic thereof, the pharmaceutical composition or the pharmaceutical preparation comprises 1-600 mg of an active ingredient M. The invention also relates to application of the pharmaceutical composition or the pharmaceutical preparation in preparation of related medicines for treating cancers.
Owner:HAISCO PHARMACEUTICAL GROUP CO LTD
Isavuconazole sulfate freeze-dried tablet and preparation method thereof
The invention belongs to the field of pharmaceutical preparations. The invention relates to a novel dosage form of an isavuconazole sulfate freeze-dried tablet, and a prescription and a process for preparing the isavuconazole sulfate freeze-dried tablet by adopting a freeze-drying method. The isavuconazole sulfate freeze-dried tablet is prepared from isavuconazole sulfate serving as a main drug and pharmaceutic adjuvants. Water is not needed during taking, and the tablet can be rapidly disintegrated after being put in the mouth and is suitable for patients with dysphagia such as old people and children; the production process of the isavuconazole sulfate freeze-dried orally disintegrating tablet is simple in technology, easy to control and suitable for industrial production.
Owner:CHONGQING MEDICAL UNIVERSITY
Energy-saving control system for drying equipment based on multi-dimensional factor analysis
This invention discloses an energy-saving control system for drying equipment based on multidimensional factor analysis, belonging to the field of intelligent control technology. The system includes: interactively obtaining the pre-drying material characteristics of the pharmaceutical excipients to be dried; pre-constructing a material drying optimization space; locating initial drying control parameters; obtaining multiple sets of equipment parameter adjustment values mapped to multiple drying stages; performing drying simulations on the pharmaceutical excipients to be dried using stage moisture content as a constraint, obtaining multiple sets of drying times, multiple sets of equipment energy consumption, and multiple sets of excipient loss rates; obtaining a target drying control array; and running the drying equipment to perform low-energy drying of the pharmaceutical excipients to be dried. This invention solves the technical problems of existing energy-saving control systems for drying equipment, which rely on fixed parameters and are difficult to accurately match the changes in the characteristics of different pharmaceutical excipients, leading to increased energy consumption and insufficient drying quality and efficiency of pharmaceutical excipients. It achieves the technical effects of effectively reducing energy consumption, improving drying efficiency, and enhancing product quality stability.
Owner:JIANGSU YOUYANG PHARM CO LTD
Chewable tablet with compound addition of probiotic fermentation and bacterial powder and preparation method of chewable tablet
The invention provides a probiotic fermentation and bacterial powder compound addition chewable tablet and a preparation method thereof, and belongs to the technical field of microorganisms, the preparation method comprises the following steps: respectively adding water into apple peel, cerasus humilis fruits and aronia melanocarpa fruits, pulping, and mixing in proportion to obtain mixed fruit pulp; a mixed bacterium solution of lactobacillus plantarum LNJ-HQ-01 and lactobacillus fermentum BNCC194390 is added into the mixed fruit pulp, and fermentation is performed; freeze-drying and grinding the fermented fruit pulp to obtain freeze-dried fruit powder; the preparation method comprises the following steps: respectively activating lactobacillus plantarum LNJ-HQ-01, lactobacillus acidophilus BNCC186447 and lactobacillus rhamnosus ATCC7469, performing enlarged culture, taking bacterial sludge, uniformly mixing the bacterial sludge with a freeze-drying protective additive, and performing freeze-drying to obtain freeze-dried bacterial powder; and uniformly mixing the fruit powder, the freeze-dried bacterial powder and the medicinal auxiliary materials, and tabletting to obtain the probiotic chewable tablets. The probiotic chewable tablet is high in dietary fiber content, effective calcium content and total phenol content, high in oxidation resistance and suitable for calcium supplement of special groups such as diabetics and the like.
Owner:LIAONING ACAD OF AGRI SCI
Method for determining trace nitrite in pharmaceutic adjuvant
The invention relates to the technical field of analytical chemistry detection, in particular to a method for determining trace nitrite in pharmaceutic adjuvants.The method comprises the steps that an acetonitrile solution, a potassium hydroxide solution, a phosphate buffer solution, a sulfuric acid solution, a 2, 3-diaminonaphthalene solution and a reference substance working solution are provided; the method comprises the following steps: preparing a standard curve solution and a test sample solution, and carrying out ultra-high performance liquid chromatography-tandem mass spectrometry analysis detection: respectively carrying out sample injection detection on the test sample solution and the prepared standard curve solutions with different concentrations under preset chromatographic conditions and mass spectrometry conditions, recording detection results of the standard curve solutions with different concentrations to make a standard curve, and calculating the content of nitrite in the test solution by adopting a standard addition method according to the standard curve and the detection result of the test solution. The method disclosed by the invention can be used for rapidly determining trace nitrite in a drug sample, and can be used for determining the trace nitrite in pharmaceutical adjuvants and detecting the nitrite in drugs.
Owner:LINGCHUAN PHARM TECH (SHANDONG) CO LTD
Excipients for self-assembling nanomaterials and methods of making and using same
PCT designated stageWO2026035369A2Chemical property predictionEnsemble learningPolyethylene glycolEngineering
Described herein is a computer-implemented method for training a machine learning model for predicting one or more physiochemical properties of a nanoparticle. In some instances, the method includes receiving a set of data including nanoparticles, generating a descriptor and fingerprint for each nanoparticle in the set of data, creating a plurality of sets of training data and a plurality of sets of test data, training a machine learning model of an artificial intelligence (AI) system using the plurality of sets of training data, and predicting a property of the drug-excipient pair of the plurality of sets of test data based on drug-excipient pairs and property values of each drug-excipient pair of the plurality of sets of training data. Also described herein are excipients conjugated to a polyethylene glycol moiety, or pharmaceutically acceptable salts thereof. In some instances, the excipients may be used to form nanoparticles with a therapeutic compound.
Owner:DUKE UNIV
Liquid oral formulations for PDE V inhibitors
The present disclosure is directed to pharmaceutical compositions comprising a PDE V inhibitor and one or more pharmaceutical excipients or additives wherein the pharmaceutical compositions are in the form of liquid pharmaceutical compositions. The pharmaceutical compositions of the present disclosure are useful for the treatment of diseases or conditions which are treatable by administration of PDE V inhibitor drug such as pulmonary arterial hypertension, erectile dysfunction, etc.
Owner:LIQMEDS WORLDWIDE LTD
A dry and sealed storage bin for pharmaceutical excipients
ActiveCN224278307URegulate humidityFlexible switchingContainers preventing decayRigid containersMedicineDesiccant
This utility model discloses a drying and sealing storage chamber for pharmaceutical excipients, including a chamber body and a storage rack. The top of the chamber body has two slots, each with a drying frame inserted into its inner side. Each drying frame has an opening at its top and a movable plate is detachably connected via bolts. The left and right drying frames are fixedly connected by a lifting frame. Two partitions are fixedly connected to the inner side of the chamber body, each partition having three ventilation slots on its surface. A fan is installed inside each ventilation slot. This utility model, by providing a detachable drying frame at the top of the chamber body, combined with the lifting frame, allows for complete removal and replacement of the desiccant without opening the chamber body. This avoids external environmental interference with the internal drying process. Compared to traditional fixed drying structures, it achieves flexible switching between drying and ventilation, improving operational efficiency.
Owner:SICHUAN BOLIHENG PHARM CO LTD
A fully dissoluble anticaries remineralization toothpaste for children and a preparation method thereof
A fully dissolvable anticaries remineralization toothpaste for children and a preparation method thereof. The toothpaste has a three-layer composite structure: a dissolvable backing protective layer, an anticaries remineralization active layer, and a pH responsive layer. All components are food grade or pharmaceutical excipient grade, and completely dissolve within 10-30 minutes in the oral environment, without the need to remove after use. The active layer contains a "fluoride-nano hydroxyapatite-xylitol" ternary synergistic system, which can inhibit demineralization, promote remineralization, and inhibit cariogenic bacteria. The active layer also contains pH-responsive food colorants, which visually indicate the end of use through color changes. Formulas are designed for children aged 3-6 and 6-12, respectively, and the toothpaste can be cut along the preset line to fit different arch sizes. The invention solves the problems of poor use compliance, high risk of swallowing, and short residence time of active ingredients in existing children's anticaries products, and achieves safe, effective, and fun oral care for children.
Owner:江西登特科技有限公司
Compound tylosin ophthalmic gel as well as preparation method and application thereof
The invention belongs to the technical field of medicines, and particularly relates to compound tylosin ophthalmic gel as well as a preparation method and application thereof. The invention relates to compound tylosin ophthalmic gel. The compound tylosin ophthalmic gel is prepared from tylosin tartrate, ganciclovir, pharmaceutic adjuvants and water, the pharmaceutic adjuvants comprise a thickening agent, a filling agent, a solubilizer, a bacteriostatic agent and a pH regulator. The compound tylosin ophthalmic gel disclosed by the invention takes effect quickly, has a remarkable treatment effect on feline conjunctivitis, has a lasting curative effect, and can still keep a relatively good drug effect after drug withdrawal.
Owner:SOUTH CHINA AGRICULTURAL UNIVERSITY
High-purity low-endotoxin pharmaceutical adjuvant sodium dihydrogen phosphate dihydrate and preparation method thereof
PendingCN121929670AInorganic non-active ingredientsPhosphorus compoundsActivated carbonSodium dihydrogen phosphate dihydrate
The invention relates to the technical field of compound refining and purification, in particular to a high-purity low-endotoxin pharmaceutical adjuvant sodium dihydrogen phosphate dihydrate and a preparation method thereof. Comprising the following steps: mixing industrial-grade sodium dihydrogen phosphate dihydrate with pure water to form a first solution; a heavy metal complexing agent is added into the first solution, and a second solution is formed after heating and stirring reaction; prefabricated activated carbon is added into the second solution, and a third solution is formed after heating and stirring reaction; and filtering the third solution while hot, concentrating under reduced pressure until a crystal film appears in the solution, naturally cooling and crystallizing, and performing solid-liquid separation to obtain the high-purity low-endotoxin pharmaceutical adjuvant sodium dihydrogen phosphate dihydrate. After refining and purification, the purity is greater than 99 wt%, the content of heavy metals is not greater than 0.0005 wt%, the content of endotoxin is lower than 2.5 EU / g, and the pharmaceutical adjuvant level is reached.
Owner:SHANGHAI WOKAI BIOTECH
Formulations of AG10
ActiveUS12539290B2Organic active ingredientsNervous disorderPharmaceutical drugCombinatorial chemistry
The present disclosure provides high-load tablet formulations of AG10 or a pharmaceutically acceptable salt thereof. In some aspects, provided herein are table formulations of AG10 or a pharmaceutically acceptable salt thereof that include at least 40% or more AG10 by weight and at least one pharmaceutical excipient selected from one or more fillers, one or more binders, one or more disintegrants, and one or more lubricants.
Owner:EIDOS THERAPEUTICS INC
Application of sodium bicarbonate in preparation of tumor immune drug enhancer
The invention discloses an application of sodium bicarbonate in preparation of a tumor immune drug enhancer. The molecular formula of the sodium bicarbonate is NaHCO3. Tumor necrosis factor alpha (TNF-alpha) is used as an anti-tumor drug to treat tumors, however, the anti-tumor efficacy of the TNF-alpha is unpredictable. It is proved that TNF-alpha activates a nuclear factor kappa B (nuclear factor kappa-light-chain-energy active B cells, NF-kappa B) signal channel, inflammatory response is enhanced, tumor cell growth is promoted, and the TNF-alpha can activate a nuclear factor kappa B (nuclear factor kappa-light-chain-energy active B cells (NF-kappa B) signal channel. Under the action of sodium bicarbonate, a TNF-alpha mediated NF-kappa B signal channel is inhibited, a TNF-alpha mediated receptor-interacting serine / threonine-protein kinase 1 (RIPK1) dependent Necroptosis signal channel is activated, and the death of tumor cells is caused, so that the TNF-alpha mediated receptor-interacting serine / threonine-protein kinase 1 (RIPK1) depends on the TNF-alpha mediated receptor-interacting serine / threonine-protein kinase 1 (RIPK1) and the TNF-alpha mediated receptor-interacting serine / threonine-protein kinase 1 (RIPK1). The prepared medicine contains a medicine excipient or a carrier allowed by a preparation. The invention develops new application of sodium bicarbonate in preparation of medicines for treating tumors. And the medicine is non-toxic to a human body after being administrated in a tumor body. Sodium bicarbonate can be used for preparing a reinforcing agent of TNF-alpha.
Owner:ZHEJIANG UNIV
A pharmaceutical excipient granulating apparatus
The utility model relates to the technical field of granulator discloses a medicinal excipient granulating equipment, including granulating box and granulating roller, the inside upper portion of granulating box is longitudinally installed with two and each other is close to of granulating roller is set up, and the transmission connection of speed reducer motor installed on the outside surface of granulating box is set up with its front end granulating box, the top of granulating box is provided with the feed hopper that communicates with the inside of granulating box, and the inside of granulating box below granulating roller is longitudinally fixed with the mesh plate that is bent into the cylinder, and the top of mesh plate is provided with the upper mouth that communicates with its inboard. The utility model technical scheme is provided with the mesh plate of the cylinder below between two granulating rollers, and the excipient of flaky particle state can be through the upper mouth and fall into the inboard of mesh plate and be moved by the paddle, and the excipient of flaky particle state can be scattered in the indentation position finally after being moved by the paddle many times, ensure that flaky material is completely broken and avoid the larger force or action speed and make granule raw material be destroyed into powder again, ensure the quality of finished product.
Owner:SICHUAN BOLIHENG PHARM CO LTD
Formulations of AG10
PendingCN122056844AOrganic active ingredientsNervous disorderPharmaceutical drugCombinatorial chemistry
The present disclosure provides a high load tablet formulation of AG10, or a pharmaceutically acceptable salt thereof. In some aspects, provided herein are tablet formulations of AG10 or a pharmaceutically acceptable salt thereof comprising at least 40% by weight or more of AG10 and at least one pharmaceutical excipient selected from the group consisting of one or more fillers, one or more binders, one or more disintegrants, and one or more lubricants.
Owner:EIDOS THERAPEUTICS INC
Novel short-chain peptide and derivative thereof
PendingCN122028898AVersatileCosmetic preparationsPeptide/protein ingredientsDiseaseAntiinflammatory drug
There is provided a compound of formula I, X-Y (I) wherein: Y comprises a peptide fragment of formula IV, [Ala] m-[Lys-V] n-Lys-V (IV) wherein m represents 0 or 1, n represents the integer 0, 1, 2, 3 or 4, and each V independently represents a sequence of 2 to 4 amino acids wherein the amino acids are selected from one or more of the group consisting of Lys, Pro, Hyp, diHyp, Thr, pThr, DOPA, Tyr and Ser; and X represents at least one optional substituent selected from the group consisting of: (i) a lipid selected from the group consisting of vitamin A, vitamin E, cholesterol and fatty acids comprising one or more carboxylic acid groups, 1 to 50 carbons and / or one or more cyclic rings, said lipids being linear or branched, saturated or unsaturated with between 1 and 10 carbon-carbon double bonds and / or substituted with between 1 and 10-OH groups, or a derivative of any of these lipids; and / or (ii) a non-steroidal anti-inflammatory agent, which compounds may be used in medicine, including as pharmaceutical excipients, adhesives and film-forming materials, and / or may be used in the treatment of conditions characterized by inflammation, including wounds, burns and mucosal disorders such as skin diseases, oral diseases, gynecological diseases and IBD.
Owner:ENLITISA (SHANGHAI) PHARM CO LTD
AG10 formulation
This disclosure provides high-load tablet formulations of AG10 or a pharmaceutically acceptable salt thereof. [Solution] In some embodiments, provided herein are tablet formulations of AG10 or a pharmaceutically acceptable salt thereof, comprising at least 40% by weight of AG10 and at least one pharmaceutical excipient selected from one or more fillers, one or more binders, one or more disintegrants, and one or more lubricants.
Owner:EIDOS THERAPEUTICS INC
Drying equipment for pharmaceutical excipient production
This utility model relates to a drying equipment for the production of pharmaceutical excipients, belonging to the field of pharmaceutical equipment technology. The equipment includes a drying cylinder, a stirring and scraping mechanism, a heat collection chamber, and a drive mechanism. The drying cylinder is inclined relative to the horizontal plane, and has an inlet and a outlet. The outlet is located at the lowest point of the drying cylinder, and the inlet is located at the highest point. The stirring and scraping mechanism is rotatably disposed inside the drying cylinder, used to stir the material and scrape off residual material on the inner wall. The drive mechanism is located at one end of the drying cylinder and connected to the stirring and scraping mechanism, used to drive the stirring and scraping mechanism to rotate. The heat collection chamber is used for collecting hot airflow. This utility model, through the design of the heat collection chamber surrounding the drying cylinder, allows the heat collection chamber to both blow hot air from the top of the drying cylinder for drying and simultaneously heat and dry the lower part of the drying cylinder through its lower part surrounding the lower part of the drying cylinder.
Owner:HENAN ZHENGHONG PHARMA ADJUVANT CO LTD
A same, 5-HTP, and st. john's wort compound nutritional supplement for emotional support and joint care
PCT designated stageWO2026115532A2Organic active ingredientsPlant ingredientsBiotechnologyVitamin b6
The present invention discloses a SAMe, 5-HTP, and St. John's wort compound nutritional supplement for emotional support and joint care, comprising 15-25 parts of S-adenosylmethionine, 5-10 parts of 5-hydroxytryptophan, 3-8 parts of St. John's wort extract, 8-15 parts of sodium chondroitin sulfate, 2-5 parts of sodium hyaluronate, 0.5-1.2 parts of vitamin B6, 1-3 parts of vitamin E, 4-9 parts of phosphatidylserine, and pharmaceutical excipients. The weight ratio of S-adenosylmethionine to 5-hydroxytryptophan is 3:1-5:2, the weight ratio of St. John's wort extract to 5-hydroxytryptophan is 0.6:1-0.8:1, and the weight ratio of the joint-care agents to the total core active ingredients is 10:3-20:3. The hypericin content in the St. John's wort extract is not less than 3%. By optimizing the component ratios and utilizing synergistic functional excipients, the present invention achieves dual synergy in emotional support and joint care, with high product stability and excellent bioavailability.
Owner:ZIRAOUI NOUR-EDDINE
A method for detecting calcium / magnesium stearate content in a preparation by ion chromatography
The present application relates to the field of pharmaceutical excipient detection, in particular to a method for quantitatively detecting calcium stearate and magnesium stearate in preparations by ion chromatography. The present application draws the standard curves of calcium / magnesium ions and excipients calcium stearate / magnesium stearate respectively, obtains the slope ratio of the two, obtains the conversion coefficient of the content of calcium / magnesium ions in calcium stearate / magnesium stearate, so as to accurately detect the content of calcium stearate or magnesium stearate in preparations. The detection method has high sensitivity, strong specificity, high precision, strong accuracy, simple and fast operation, wide applicability, low detection cost, realizes the quantitative detection of common excipients calcium stearate / magnesium stearate in preparations, thereby effectively guiding the self-prepared preparations to be consistent with the reference preparation prescription.
Owner:HUBEI GUANGJI PHARMA +1
Cathepsin B targeting medicine and application thereof in autism treatment
InactiveCN121570444ACompounds screening/testingNervous disorderInflammatory factorsCathepsin B activity
The invention relates to the technical field of biological medicine, in particular to a medicine for targeting cathepsin B and application of the medicine in autism treatment. The medicine is prepared into an oral or injection preparation by synthesizing a small-molecule inhibitor with high selectivity and combining with pharmaceutic adjuvants, so that the activity of cathepsin B can be effectively inhibited, neuroinflammation can be relieved, and synaptic function balance can be recovered. Experiments show that the medicine remarkably improves social behavior defects and repetitive behaviors of BTBR T + Itpr3tf / J mice, and meanwhile, the activity of cathepsin B and the level of inflammatory factors in brain tissue are reduced. The dosage of the composition is 0.1-10 milligrams per kilogram of body weight, the administration route comprises oral administration or injection, and the storage condition is that the composition is stored in a dark place at the temperature of 2-8 DEG C. The invention provides a clear action mechanism and a remarkable treatment effect.
Owner:XIN HUA HOSPITAL AFFILIATED TO SHANGHAI JIAO TONG UNIV SCHOOL OF MEDICINE
Oral vaccine via dental bacteria and emitted peptides to prevent COVID-19 infection
ActiveUS12539328B2SsRNA viruses positive-senseViral antigen ingredientsPharmaceutical AidsTGE VACCINE
Disclosed is a pharmaceutical composition to prevent transmission of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the pharmaceutical composition comprising: genetically modified bacteria; sequences of small peptides; and pharmaceutical excipients, wherein the genetically modified oral bacteria are modified to translate, produce, and emit the sequences of small peptides which neutralize SARS-CoV-2 against COVID-19, wherein transgenic technology is used to modify the genetically modified oral bacteria to add genes in genetically modified oral bacteria that are transcribed to produce small peptides from the sequences of small peptides so added, wherein the sequences of small peptides show extreme binding and neutralization to SARS-CoV-2 but not to host proteins or processes, and wherein the pharmaceutical excipients aid the oral and / or nasal administration of the pharmaceutical composition.
Owner:KOTLYAR DAVID
Composition for treating eye disorders
A composition for use in treatment of ocular disorders is provided, comprising human keratinocyte growth factor-2 (hKGF-2) and a stabilizing agent, wherein the stabilizing agent comprises one or more of: 0.1% to 2% (w / v) mannitol or 0.01% to 0.05% (w / v) sodium hyaluronate; 0.1% to 2% (w / v) glycerol; 0.1% to 2% (w / v) trehalose or 0.5% (w / v) human serum albumin; and 0.1% to 2% (w / v) lysine hydrochloride. The compatibility between the hKGF-2 stock solution and pharmaceutical excipients was systematically studied to determine optimal concentration ranges for the stabilizing agent, surfactant, and pH-regulator. Based on these ranges, the denaturation (melting) and aggregation temperatures of hKGF-2 in the solution system were evaluated to establish an optimized formulation, in which the biological activity of hKGF-2 is maintained for an extended period. Compared with existing eye drop formulations, the hKGF-2 eye drops of the present disclosure demonstrate improved efficacy in the treatment of dry eye disease.
Owner:WENZHOU MEDICAL UNIV +1
Methyl methacrylate-butyl methacrylate copolymers and methods for their preparation
PendingCN122127529AEster polymer adhesivesPharmaceutical non-active ingredientsPolymer scienceMethacrylate methyl
The application belongs to the technical field of pharmaceutical excipients, and particularly relates to a methyl methacrylate-butyl methacrylate copolymer and a preparation method thereof; the monomer molar ratio of methyl methacrylate to butyl methacrylate in the copolymer is about 1:2.5-1:3.4, and the butyl methacrylate-methyl methacrylate copolymer has the following structure. The butyl methacrylate-methyl methacrylate copolymer with better adhesion and higher stability is prepared by limiting the monomer ratio, molecular weight and viscosity of the copolymer; and the preparation method of the butyl methacrylate-methyl methacrylate copolymer has the comprehensive advantages of high heat dissipation efficiency, excellent product form and simple post-treatment.
Owner:HUNAN PEGLAN PHARMACEUTICAL CO LTD
Application of theabrownin extract in preparation of products for improving cognitive impairment
PendingCN121868386ANervous disorderNatural extract food ingredientsNew medicationsPharmaceutical drug
The invention belongs to the field of biological medicines, and discloses application of a theabrownin extract in preparation of a product for improving cognitive impairment. The theabrownin extract can improve learning and memory ability and / or spatial memory ability, thereby improving cognitive impairment. The new application of the theabrownin extract is found, and it is verified that the theabrownin extract can be used as a medicine for preventing and treating cognitive impairment and particularly can be used for preparing a medicine for preventing and treating senile dementia. The pharmaceutical composition can be prepared into various dosage forms with proper pharmaceutic adjuvants, and is suitable for being developed into new drugs. The theabrownin is derived from tea and has safety, the theabrownin extract can be developed into functional food for daily eating or drinking, and the application range of the theabrownin extract is widened.
Owner:HUAZHONG UNIV OF SCI & TECH
A blasting bead toothbrush
This invention belongs to the field of pharmaceutical preparations containing organic active ingredients, specifically relating to the manufacture of pharmaceutical excipients. It relates to a toothbrush with burst beads, comprising: a toothbrush handle and a brush head, the toothbrush handle being connected to the brush head. The brush head has a burst bead storage cavity, which is filled with functional burst beads. Each functional burst bead comprises: a shell and contents, the contents being composed of the following raw materials in parts by weight: 1-2 parts of the above-mentioned fig polyphenol extract, 0.3-0.5 parts of vitamin C, 1-3 parts of propylene glycol, 88-90 parts of glycerin, and 1.5-2 parts of water. This invention uses a natural eutectic solvent composed of glycerin / fructose / lysine to extract fig polyphenols as the core functional ingredient of the burst beads, possessing both strong antioxidant, broad-spectrum antibacterial, and adjunctive therapeutic effects on oral ulcers. Furthermore, the ingredients are natural, non-irritating, convenient to use, and highly hygienic, solving the problems of traditional oral care products having limited functionality and leaving artificial solvent residues.
Owner:SHANDONG MIAOZHU BIOTECHNOLOGY CO LTD
A preheating tank for pharmaceutical excipient production
ActiveCN224278433Ueasy dischargeAvoid jamming of valvesLarge containersThermodynamicsElectric machinery
This utility model relates to the field of excipient preheating technology, and discloses a preheating tank for pharmaceutical excipient production, including a support frame. A preheating tank is detachably mounted on the upper end of the support frame. A cover plate is provided on the upper end of the preheating tank, and a stirring motor is fixedly mounted on the upper end of the cover plate. A discharge channel is connected to the lower end of the preheating tank. A sealing component for blocking the discharge channel is provided on one side of the preheating tank, and a limiting component for supporting and limiting the stirring motor is provided on one side of the cover plate. This utility model's technical solution allows the fixed plate to be pulled to the left, simultaneously stretching the return spring, causing the fixed plate to separate the baffle from the discharge channel. This facilitates the discharge of preheated pharmaceutical excipients through the discharge channel, avoiding the situation where pharmaceutical excipients get stuck in the valve when using valve control, and also eliminates the inconvenience of workers tilting the preheating tank to pour out the pharmaceutical excipients.
Owner:SICHUAN BOLIHENG PHARM CO LTD
Medicinal auxiliary material screening device
Owner:HARBIN CHILDRENS PHARM FACTORY CO LTD
Filtering equipment for pharmaceutic adjuvants
The utility model discloses filtering equipment for pharmaceutical excipients, which comprises a sleeve, a mounting strip and a filter screen, a plurality of groups of through holes are formed in one side of the sleeve, an extrusion device is arranged in the sleeve, the mounting strip is mounted on one side of the sleeve, a plurality of groups of mounting grooves are formed in one side of the mounting strip, the through holes are overlapped with the mounting grooves, and the filter screen is arranged in the sleeve. A telescopic device is arranged in the mounting strip, first sliding strips are mounted on the two sides of the filter screen, multiple sets of clamping grooves are formed in the surfaces of the first sliding strips, the filter screen can be rapidly disassembled and assembled through the arranged extrusion device and the telescopic device, and the problem that the working efficiency is affected due to the fact that existing filtering equipment is inconvenient to disassemble is solved.
Owner:SHANDONG LIUJIA PHARM EXCIPIENT CO LTD
Oral solid controlled release formulation based on microdroplet ejection and method of preparation thereof
ActiveCN115966265BSolve the problem of inability to achieve ideal controlled release effectScientific and reasonable designAdditive manufacturing apparatusMolecular designComputer printingPharmaceutical Aids
The application belongs to the field of drug design, and discloses a preparation method of oral solid controlled-release preparation based on micro-droplet spraying, comprising the following steps: S1, separating and designing the distribution of active pharmaceutical ingredients and pharmaceutical excipients in the preparation; S2, recombining the ingredient information after the separation and design; S3, converting the ingredient distribution information after the combination into a slice recognizable by a 3D printing device; S4, printing by using a double-channel micro-droplet spraying 3D printer; and S5, using a powder material to receive the ingredients sprayed by the printer, so as to bond and form a solid preparation. The concentration gradient function defined by the application defines the concentration distribution method of the active pharmaceutical ingredients in the preparation, and solves the problem that the controlled-release preparation cannot achieve ideal controlled-release effect in principle; the 3D printing of the oral solid controlled-release preparation by using the double-channel micro-droplet spraying principle can change the existing preparation process mode, and can prepare the oral solid controlled-release preparation meeting the functional design requirements.
Owner:XI AN JIAOTONG UNIV